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Highly pathogenic H5N1 virus infection causes severe disease and a high rate of fatality in humans.
Development of humanized monoclonal antibodies may provide an efficient therapeutic regime for H5N1 virus
infection. In the present study, broadly cross-reactive monoclonal antibodies (MAbs) derived from mice were
humanized to minimize immunogenicity. One chimeric antibody (cAb) and seven humanized antibodies (hAbs)
were constructed. These antibodies retained broad-spectrum reactivity to H5N1 viruses, binding to recombi-
nant H5-subtype HA1 molecules expressed in CHO cells in a dose-dependent manner and exhibiting similar
reactivities against antigenically distinct H5N1 viruses in hemagglutination inhibition (HI) assays. One
humanized antibody, 37 hAb, showed HI and neutralization activities comparable to that of the parental
murine antibody, 13D4 MAb, while the other six antibodies were less reactive to H5N1 viruses. Analysis of
amino acid sequences in the variable region frameworks of the seven humanized antibodies found that Q5 and
Y27 in the VH region are highly conserved murine residues. Comparison of the three-dimensional structures
derived from the variable regions of MAbs 37 hAb, H1202-34, and 13D4 revealed that residue substitutions at
sites 70 and 46 may be the major cause for the observed differences in binding affinity. Examination of the
chimeric antibody and one of the humanized antibodies, 37 hAb, showed that both antibodies offered postin-
fection protection against lethal challenge with antigenically diverse H5N1 viruses in the mouse model.
Chimeric and humanized antibodies which retain the broadly reactive and protective properties of murine
H5-specific monoclonal antibodies have great potential for use in the treatment of human H5N1 infection.
Avian influenza viruses rarely cause human infection (4).
However, sporadic human infections with H5N1, H7N7, and
H9N2 avian influenza viruses have been reported in recent
years (5, 9, 29). While human infections with H7N7 virus were
identified only in the Netherlands in 2003 and H9N2 infection
results in only mild disease, the highly virulent avian H5N1
virus causes severe and sometimes lethal illness in humans
(23). The persistent prevalence of avian H5N1 viruses in poul-
try is the reason why sporadic cases of human infection con-
tinue to occur (1, 34). According to a recent report from the
World Health Organization (WHO), avian H5N1 virus has
caused 505 cases of human infection, 300 (59%) of which were
fatal, in 12 countries since 2003 (37). There is concern that
avian H5N1 virus may either mutate or form a reassortant virus
by combining with other human influenza viruses, thereby ac-
quiring the capacity for efficient human-to-human transmis-
sion. Preparedness for a potential outbreak or pandemic
caused by highly pathogenic influenza virus is essential.
There are two main classes of drugs available for preventing
and/or treating influenza virus infection: the M2 ion-channel
blockers and the neuraminidase inhibitors. Resistance to the
M2 ion-channel blockers, amantadine and rimantadine, is reg-
ularly detected among influenza viruses (20, 24). While resis-
tance to one of the neuraminidase inhibitors, oseltamivir, was
rare among the pandemic 2009 (H1N1) virus and seasonal
H1N1 influenza viruses prior to 2007, a resistant H1N1 variant
has emerged and replaced the susceptible wild-type virus, be-
coming the dominant population worldwide since 2007 (19,
20). Although animal tests show that oseltamivir can inhibit
H5N1 virus replication effectively, clinical data from a limited
number of human cases could not demonstrate clear efficacy
for this treatment (8, 32). More effective treatments are nec-
essary for combating acute viral infections such as those caused
by the highly pathogenic H5N1 virus.
Passive immunotherapy is a treatment strategy used for a
range of human diseases (18). The first antibody drug ap-
proved for the treatment of an infectious disease is palivi-
zumab (Synagis), for respiratory syncytial virus infection (11).
Passive immunotherapy has also played a key role in the treat-
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ment of disease caused by influenza viruses. Transfusion of
human blood products from convalescing survivors reduced
the mortality rates by 50% during the 1918 Spanish flu pan-
demic, and more recently, several severely ill H5N1 virus-
infected patients were cured using plasma from convalescing
survivors or vaccine recipients (17, 35, 39). The potential for
application of monoclonal antibodies (MAb) in the treatment
of H5N1 virus infection has been extensively investigated (7,
13, 26, 28). However, avian H5N1 viruses have continued to
circulate in different regions in different genetic and antigenic
variant forms since 2003, posing a considerable challenge to
the development of therapeutic antibodies. It is therefore nec-
essary to develop broadly cross-neutralizing MAbs that will
recognize genetically and antigenically diverse H5N1 viruses.
The hemagglutinin antigen (HA) is a homotrimeric surface
protein comprised of the HA1 and HA2 subunits. The HA1
subunit is responsible for viral binding to host receptors and
serves as the principal target for neutralizing antibodies. HA1
is known to undergo rapid genetic and antigenic evolution in
order to evade host immunity. The HA2 subunit, which is
primarily responsible for mediating the fusion of viral and cell
membranes, is relatively conserved among different subtypes of
influenza viruses. While most H5N1-specific antibodies have
been found to target the HA1 region (7, 21, 25, 31), several
recent studies have reported on antibodies with the potential
to neutralize influenza viruses of different subtypes by target-
ing the HA2 region of the HA protein (10, 12, 15, 30, 33).
It is possible that antibodies which can bind to HA2 may
possess broad cross-reactivity. However, antibodies to HA1,
which contains the dominant antigenic epitopes, are more ef-
fective at neutralizing rapidly replicating influenza viruses,
such as the H5N1 subtype. It is important to identify antibodies
which exhibit high affinity for the HA of H5N1 virus and which
are also able to neutralize different antigenic variants of H5N1.
Our previous study reported on a panel of 52 broadly cross-
reactive H5-specific MAbs. One of these antibodies, 13D4
MAb, showed inhibitory activity against 41 H5N1 isolates
which represented all of the major genetic clades/subclades of
avian H5N1 viruses characterized since 1997. This antibody
also protected mice against lethal challenge with four H5N1
strains belonging to the major genetic populations currently
causing human infections. More importantly, 13D4 MAb pos-
sesses extremely potent neutralizing activity against H5N1,
even at the stage of infection when the virus has disseminated
beyond the pulmonary system. The strong neutralizing and
cross-reactive abilities exerted by 13D4 MAb may be attribut-
able to its binding at two conserved sites within the globular
head of the HA molecule (7). Of the panel of H5-specific
antibodies that we have developed, 13D4 MAb neutralizes the
broadest spectrum of H5N1 viruses and shows the most po-
tential therapeutic value for controlling infections caused by
current and future H5N1 variants. In the present study, we
have humanized the murine 13D4 antibody by combining the
variable region of 13D4 MAb with a human constant region
using complementarity-determining region (CDR) grafting
and combinatorial library screening and demonstrate that the
chimeric and humanized versions of 13D4 antibody maintain
the broad-spectrum reactivity and effectiveness in protecting
mice against lethal H5N1 challenge of the original murine
version.
MATERIALS AND METHODS
Virus. The H5N1 viruses used in this study were selected from different
phylogenetic clades/subclades and grown in 10-day-old specific-pathogen-free
embryonated chicken eggs at 35°C for 30 h. Allantoic fluids were harvested and
kept at 80°C until use. Virus titers were determined by infection of MDCK cells
and are expressed as the 50% tissue culture infectious dose (TCID50) per mil-
liliter, in accordance with the method of Reed and Muench (27). All experiments
involving live virus were conducted in a biosafety level 3-enhanced containment
facility at the University of Hong Kong.
Humanization of 13D4 MAb. (i) Cloning of 13D4 MAb V-region genes. 13D4
MAb, which recognizes the hemagglutinin of highly pathogenic H5 avian influ-
enza virus, was developed and purified at the National Institute of Diagnostics
and Vaccine Development in Infectious Diseases, School of Life Sciences, Xia-
men University. mRNA was prepared from 13D4 MAb hybridoma cells and used
in first-strand cDNA synthesis with oligo(dT) primer (Promega, Madison, WI).
The total cDNA was used as a template to amplify both the variable heavy- and
light-chain genes using an Ig-Prime kit from Novagen Company (Darmstadt,
Germany). The resultant products were cloned into pMD18-T (Takara, Japan)
for sequencing.
(ii) Humanization of MAb. Humanization of 13D4 MAb was performed using
CDR grafting and combinatorial library screening. Human germ line immuno-
globulin sequences were sourced from the International Immunogenetics Infor-
mation System (IMGT) database (3). The human germ line light- and heavy-
chain sequences with the highest degree of homology with 13D4 MAb framework
regions of each chain were selected using distances-compute pairwise analysis
(MEGA, version 3.1, software; The Biodesign Institute, Tempe, AZ). The 6
CDRs of 13D4 MAb were then grafted to the selected human germ line frame-
works. A combinatorial phage library was then constructed to identify the key
amino acids which should be changed back to the murine sequence in the
humanized framework. We identified mismatched residues either near the CDR
regions or with differences in physical and chemical properties and included both
the human and murine alternatives at these sites in the combinatorial library. For
other mismatched residues, the human version was retained.
Full-length humanized V-region genes were generated by splicing overlapping
extension PCR products for insertion into the pCANTAB 5E variable fragment
(single-chain Fv [scFv]) vector (Pharmacia Biotechnology). Codons for the mu-
rine and human alternatives at library positions were included in the synthesis of
the humanized V-region oligonucleotides. The library was generated after elec-
troporation into bacterial strain ER2738 (NEB). Library panning was carried out
using the H5N1 virus Ck/HK/YU22/2002 (YU22), captured by MAbs precoated
on microtiter plates. Humanized antibodies (hAbs) were selected by phage
enzyme-linked immunosorbent assay (ELISA), using either YU22 captured by
MAbs specific for H5N1 HA or CHO-expressed recombinant HA1 coated onto
microtiter plates.
(iii) Construction of chimeric and humanized IgG1 expression plasmids. The
Flp-In system (Invitrogen) was used to generate stable mammalian expression
cell lines by Flp recombinase-mediated integration. The pcDNA5/FRT/TO vec-
tor (Invitrogen) was modified to incorporate two PCMV promoters, a cloning site,
and bovine growth hormone and polyadenylation signal (BGH pA) to allow
expression of antibody heavy and light chains by the same plasmid. The genes
encoding the human gamma and kappa constant regions were separately inserted
downstream of the two PCMV promoters.
Sequence-specific primers were then designed and used to amplify the
variable regions of the mouse antibody and humanized antibodies, which
were then cloned into the above-mentioned expression vector in frame with
the constant regions. Expression of this construct leads to the production of
chimeric antibodies (cAbs) or humanized antibodies containing human IgG1
constant regions.
(iv) Generation of stably expressing CHO cell line. The pOG44 plasmid
(Invitrogen) and the chimeric or humanized IgG1 expression plasmids were
cotransfected into the Flp-In CHO cell line (Invitrogen). Upon cotransfection,
the Flp recombinase expressed from pOG44 mediated a homologous recombi-
nation event such that the IgG1 expression construct was inserted into the
genome at the integrated Flp recombination target site. Stable cell lines express-
ing chimeric or humanized IgG1 were selected on the basis of hygromycin
resistance and expression of the chimeric or humanized antibody.
(v) Expression and purification of chimeric and humanized antibodies. Chi-
meric or humanized antibodies were expressed by the stable CHO cell lines in
serum-free SFM4 medium (HyClone, Australia). The stable CHO expression
cells were first grown to 3  106/ml in Dulbecco modified Eagle medium con-
taining 10% fetal bovine serum, which was then changed to serum-free SFM4
medium, and supernatants were collected after a further 5 to 7 days. The chi-
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meric and humanized antibodies were purified using protein A-Sepharose beads
(Millipore). The purity of the chimeric and humanized antibodies was confirmed
by SDS-PAGE using BandScan software (version 5.0).
Reactivities of chimeric and humanized antibodies with viral antigen. (i)
Binding activity assay. Serial dilutions of chimeric and humanized antibodies
(initial concentration, 25 g/ml) were added to microplate wells coated with
recombinant HA1 expressed by CHO cells (200 ng/well). The unrelated 4D11
cAb to the hepatitis B virus (HBV) pre-S1 region was used as a negative control,
and goat anti-human–horseradish peroxidase (HRP) (1:2,000) was used as the
secondary antibody.
(ii) Competitive ELISA. The H5N1 virus YU22 was captured by antibodies
coated on microplate wells, and then serial dilutions of chimeric or humanized
antibodies (initial concentration, 50 g/ml) and HRP-conjugated parent anti-
body were added simultaneously and allowed to compete for virus binding. The
unrelated 4D11 cAb to HBV pre-S1 was used as a negative control, and parent
antibody alone was used as a positive control.
(iii) HI tests. Hemagglutination inhibition (HI) was performed to assess an-
tibody reactivity against different H5N1 isolates, in accordance with the World
Health Organization Manual on Animal Influenza Diagnosis and Surveillance,
modified as previously described (36, 38).
Molecular modeling of three-dimensional (3D) structures of Fvs. Fvs of the
murine anti-HA antibody (13D4 MAb) and humanized antibodies (37 hAb and
H1202-34) were built using homology modeling. BLAST searches of the Protein
Data Bank (PDB) for light-chain and heavy-chain sequences were performed.
Because the templates of 13D4 MAb exhibited higher identities than the two
humanized antibodies, this antibody was modeled first and the modeled structure
was then further used as a template for modeling of 37 hAb and H1202-34.
Homology modeling of the light chains and heavy chains of the three Fv struc-
tures was performed separately using Discovery Studio software (Acceryls, San
Diego, CA). Low-identity regions with more than 4 contiguous mismatched
amino acids were optimized separately using the Model Antibody Loops module.
The light chain and heavy chain were then placed together by superimposition
onto one of the template models. The initial structure was subjected to 1,000
steps of steepest descent and 2,000 steps of conjugate gradient minimization
under a CHARMm force field. Bump checks were performed, and unreasonable
bumps were removed using the Side-Chain Rotating tool (Discovery Studio).
The quality of the homology models was determined by examining the distribu-
tion of amino acid residues in a Ramachandran plot.
Therapeutic efficacy of 13D4 chimeric and humanized antibodies in a mouse
model. The protocol for the animal experiments was approved by the Ethical
Committee for Laboratory Animals at Xiamen University. Groups of 6 BALB/c
mice aged 6 to 8 weeks were anesthetized with isoflurane and then inoculated
intranasally with 10 times the 50% mouse lethal dose (MLD50) of H5N1 strain
A/VNM/1194/2004, A/BH Goose/QH/15C/2005, A/IDN/5/2005, or A/SZ/406H/
2006. 13D4 cAb or humanized antibody was diluted in phosphate-buffered saline
(PBS) to a final volume of 100 l and at 24 h after inoculation was intravenously
injected via the tail vein at a dose of 20 mg per kg of body weight. Animals in the
control group were injected with an equivalent volume of PBS at 24 h after
infection. To determine the dose response, additional groups of mice challenged
with 10 MLD50s of the A/BH Goose/QH/15C/05 strain received 13D4 cAb or
hAb at doses of 5 mg/kg or 10 mg/kg at 24 h postinfection. Animals were
observed daily for morbidity and mortality, and body weights were measured for
up to 14 days following infection.
RESULTS
Humanization of 13D4 MAb. 13D4 MAb was previously
shown to have broadly cross-protective properties against an-
tigenically distinct variants of H5N1 viruses in a mouse model
(7). In the present study, variable region genes were cloned
from 13D4 hybridoma cells, and humanized 13D4 antibodies
were generated using CDR grafting and combinatorial library
screening techniques. The human germ line light- and heavy-
chain sequences 1-39-01 and 1-69-04 were selected as the
framework for CDR grafting, as they showed the highest de-
gree of homology with the corresponding regions of 13D4
MAb framework (Fig. 1). There are 12 and 8 mismatched
residues in the VH and VK framework regions, respectively,
between 13D4 MAb and selected human germ line sequences.
These residues either near the CDRs or with differences in
physical and chemical properties were accommodated by in-
corporating both human and murine alternatives in the design
of the combinatorial library. Other mismatched residues were
retained in the human configuration. A phage scFv library with
an actual capacity of 1  107 PFU was constructed and
screened against the YU22 strain of H5N1 virus (7). Human-
ized antibodies were selected by phage ELISA. Seven phage
clones which tested positive for binding reactivity to YU22 and
the recombinant HA1 protein were selected (Fig. 2). The
aligned amino acid sequences of the seven humanized antibod-
ies are shown in Fig. 1.
Reactivity of chimeric and humanized antibodies with viral
antigen. The Flp-In system was used to generate mammalian
cell lines that stably express chimeric and humanized IgG1.
The chimeric and humanized antibodies were expressed in
serum-free medium, and the antibodies were then purified to
FIG. 1. Alignment of amino acid sequences of variable region frameworks of the murine 13D4 MAb, human germ line sequences, and
humanized antibodies. The human germ line light- and heavy-chain sequences 1-39-01 and 1-69-04 were selected as the framework for CDR
grafting. The seven humanized antibodies identified in this study were designated 37 hAb, H1202-34, H8, H1121-37, H1108-18, H1213-21, and
Y1121-29. The dashed lines represent amino acids that are identical to residues in the human germ line sequences.
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95% homogeneity using protein A-Sepharose beads for use
in the following experiments.
The purified 13D4 chimeric and humanized antibodies ex-
pressed by CHO cells bound to recombinant HA1 in a dose-
dependent manner (Fig. 3). Two of the humanized antibodies,
37 hAb and H1126-08, showed the highest binding activity with
HA1, while another humanized antibody, H1202-34, exhibited
the lowest reactivity with HA1. In a competitive ELISA, the
parental 13D4 MAb, the chimeric antibody (cAb 13D4), and
37 hAb and H1202-34 but not the control antibody (4D11 cAb)
blocked the binding of HRP-labeled 13D4 MAb to YU22 virus
(Fig. 4).
H5 broad-spectrum cross-reactivity of 13D4 chimeric and
humanized antibodies in hemagglutinin inhibition test. Four-
teen H5N1 virus strains belonging to seven major genetic
clades/subclades were used to verify if 13D4 chimeric and
humanized antibodies retain broad-spectrum H5 reactivity in
the HI test (Table 1). Similar HI reactivities were observed for
13D4 cAb, 37 hAb, and the parent antibody in their binding to
all 14 of the H5N1 virus strains used in the test, indicating that
13D4 cAb and 37 hAb retain the broad-spectrum reactivity and
affinity of the parental murine antibody. The other six human-
ized antibodies also showed cross-reactivity but showed lower
titers, indicating a decreased affinity for binding to virus.
Homology modeling of 3D structures of variable fragments
of 13D4 MAb, 37 hAb, and H1202-34. Of the seven humanized
antibodies, 37 hAb showed the highest activity in the indirect
ELISA, where binding to recombinant HA1 protein expressed
from CHO cells was tested, and also in the competitive ELISA,
which tested binding to the YU22 H5N1 virus. Another hu-
manized antibody, H1202-34, showed the lowest binding activ-
ity and reactivity in the ELISA and the HI test, respectively.
While 37 hAb retains 16 murine residues in the framework
regions, the H1202-34 antibody retains only 8 (Fig. 1). Com-
puterized 3D structures of the variable fragments of 13D4
MAb and these two humanized antibodies were built using
homology modeling to analyze the structural basis for the dif-
ference in binding activity. Using the PDB BLAST search tool,
we selected structures reported by different laboratories and
obtained the homology modeling templates using different
methods. In the light-chain templates, the average identities
are about 80% to 90% and no unaligned loop regions were
detected. For the heavy-chain templates, the average identity is
only about 75%, and the loop region could be detected on
CDR2 and CDR3 (more than 4 residues). 13D4 MAb was
analyzed first, and the modeled structure of 13D4 MAb was
FIG. 2. The humanized antibody clones obtained using a phage
display system showed reactivity against both YU22 virus and recom-
binant HA1 protein in ELISAs. Phage clones were tested against
CHO-expressed recombinant HA1 protein coated on microtiter plates
or the H5N1 virus YU22 captured by specific MAbs coated on micro-
titer plates. M13K07 phage was used as a negative control. The phage
clones that reacted with both YU22 virus and recombinant HA1 were
identified as positive clones. OD, optical density.
FIG. 3. The purified 13D4 chimeric and humanized antibodies
bound to recombinant HA1 protein in a dose-dependent manner.
Serial dilutions of chimeric and humanized antibodies were added to
microplates coated with recombinant HA1 protein. The 4D11 cAb to
HBV pre-S1 was used as a negative control, and GAH-HRP was used
as the secondary antibody. Tests were performed in triplicate, and
results are expressed as mean absorbance  standard deviation. OD,
optical density.
FIG. 4. The 13D4 chimeric and humanized antibodies blocked the
binding of HRP-labeled 13D4 to an H5N1 virus in the competitive
ELISA. The H5N1 virus YU22 was captured by antibodies precoated
on microplates, and then serial dilutions of the chimeric or humanized
antibodies and HRP-conjugated parental 13D4 antibody were simul-
taneously added to the plate to compete for binding to the captured
H5N1 virus. The 4D11 cAb to HBV pre-S1 was used as a negative
control, and parental 13D4 antibody alone was used as a positive
control. Tests were done in triplicate, and results are shown as mean
absorbance  standard deviation. OD, optical density.
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then further used as a template for modeling of 37 hAb and
H1202-34.
The modeled structures of 37 hAb and H1202-34 are shown
in ribbon mode in Fig. 5. Ramachandran plots of each final
model showed that most of the backbone angles are in the
allowed region. Ignoring glycine, only three residues are de-
tected in the disallowed region: 13D4 MAb:VH:Thr102, 37
hAb:VH:Ala103, and H1202-34:VH:Ala103. The root mean
square differences of 37 hAb and H1202-34 with 13D4 MAb
are 0.437 and 0.494, respectively. By superimposing the 37 hAb
and H1202-34 models onto 13D4 MAb structures, each mis-
matched residue in 37 hAb and H1202-34 was examined for its
tendency to disrupt the original folding. Most of these residues
fit well at their positions and may not affect the adjacent
paratope; the exceptions were H70 and L46. H:F70I was ob-
served on H1202-34, which has lost most of the binding activity
of the parent antibody. The phenyl of H70:F on 13D4 MAb
and 37 hAb may form weak van der Waals interactions with the
adjacent CDR residues (H60:Y, H58:I, H50:E) (Fig. 6a). For
H1202-34, the absence of phenyl may result in a collapse in this
region (CDR-H2). L46:L on H1202-34 is another key residue
which might alter the antibody paratope. The long leucine side
chain may push the phenyl of H109:Y (CDR-H3) and L55:Y
(CDR-L2) away and form van der Waals interactions with
them (Fig. 6b and c). As this interaction involves both the light
chain and heavy chain, the mismatched residue may also affect
the overall stability of the variable fragment.
Therapeutic efficacy of 13D4 chimeric and humanized anti-
bodies in a mouse model. 13D4 cAb and 37 hAb were exam-
ined for their ability to protect mice against infection with
antigenically distinct H5N1 viruses from clades 1, 2.1, 2.2, and
2.3. Groups of 6-week-old female mice were challenged with
lethal doses of different strains of H5N1 viruses and then
treated with 20 mg/kg of 13D4 chimeric or humanized antibody
or PBS placebo at 1 day postinfection. All of the control ani-
mals, which received only PBS, exhibited continuous weight
loss following virus challenge and died on day 7 or 8 postin-
fection. Administration of antibody 1 day after virus challenge
was found to arrest the weight loss caused by all 4 of the
different H5N1 virus strains, with mice rapidly recovering and
gaining weight. The chimeric and humanized antibodies af-
forded 100% protection against infection with three of the
TABLE 1. HI analysis of 13D4 cAb and hAbsa
H5N1 strain Clade
Antibody titer
13D4 MAb 13D4 cAb H8 37 H1121-37 H1202-34 Y1213-21 H1121-29 H1108-18 H1-18G9
VNM/1194/2004 1 1,600 800 400 3,200 800 400 400 400 400 10
HK/213/2003 1 12,800 6,400 6,400 12,800 1,600 1,600 3,200 1,600 3,200 10
DK/VNM/283/2005 1 3,200 1,600 800 3,200 1,600 400 800 400 800 10
CK/IDN/2A/2004 2.1 12,800 6,400 6,400 6,400 6,400 1,600 1,600 6,400 3,200 10
Indonesia/5/2005 2.1 6,400 3,200 1,600 3,200 1,600 400 800 1,600 1,600 10
DK/IDN/MS/2004 2.1 6,400 1,600 800 1,600 400 200 800 800 800 10
CK/Bantul/BBVet-1/2005 2.1 3,200 1,600 800 3,200 400 400 800 800 800 10
BHGS/QH/15/2005 2.2 6,400 3,200 3,200 3,200 3,200 800 1,600 1,600 1,600 10
CK/VNM/568/2005 2.3 6,400 3,200 800 6,400 1,600 400 800 1,600 1,600 10
CK/GY/3570/2005 2.3 3,200 3,200 800 3,200 1,600 400 800 800 1,600 10
Shenzhen/406H/2006 2.3 6,400 1,600 1,600 3,200 800 800 800 400 400 10
CK/YN/115/2004 2.4 6,400 1,600 1,600 6,400 800 800 800 400 800 10
A/CK/HK/YU22/2002 8 3,200 1,600 800 3,200 800 400 400 400 400 10
MDK/JX/1653/2005 9 3,200 800 800 1,600 800 400 400 400 400 10
New Caledonia/20/1999 (H1N1) 10 10 10 10 10 10 10 10 10 3200
a Purified 13D4 murine, chimeric, and humanized antibodies at a concentration of 2 mg/ml were titrated in a hemagglutination inhibition assay against 14 H5N1
isolates belonging to seven of the major genetic clades/subclades of H5N1 viruses. H1-18G9 against New Caledonia/20/1999 (H1N1) was used as a negative control.
Serial 2-fold dilutions of each antibody were made, and the highest dilution that inhibited hemagglutination was read as the HI titer of the antibody. BHGS, bar-headed
goose; CK, chicken; Dk, duck; Gs, goose; GY, Guanyang; HK, Hong Kong; IDN, Indonesia; JX, Jiangxi; MDk, migratory duck; QH, Qinghai; VNM, Vietnam; YN,
Yunnan.
FIG. 5. Fv structures of the humanized antibodies 37 hAb (a) and
H1202-34 (b). Mutations are rendered in stick mode and colored
according to atom type. The CDRs of each chain are yellow.
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strains, A/VNM/1194/2004 (clade 1), A/BH Goose/QH/15C/
2005 (clade 2.2), and A/SZ/406H/2006 (clade 2.3), and 83%
protection against a high dose of A/IDN/5/2005 (clade 2.1)
(Fig. 7). Previous studies using HIV MAb did not prevent
mortality (7). To examine if lower doses of 13D4 chimeric and
humanized antibodies also provided protection against H5N1
virus infection, mice were inoculated with a lethal dose (10
MLD50s) of A/BH Goose/QH/15C/2005 virus, followed by in-
travenous injection of 5 mg/kg or 10 mg/kg of antibody at 1 day
postinfection. Both the chimeric and humanized antibodies
showed 100% protection of infected mice at these reduced
doses.
DISCUSSION
Highly pathogenic avian H5N1 virus has caused more than
500 confirmed human infections, with approximately 60% re-
sulting in death, according to the World Health Organization.
Currently, there is no effective treatment for H5N1 virus in-
fection, and the efficacy of neuraminidase inhibitors, the prin-
cipal anti-influenza drugs, is not clear. Passive immunotherapy
has increasingly been used in the treatment of infectious dis-
eases in recent years (1). There are reports of antisera from
patients who have recovered from H5N1 virus infection or
from H5N1 vaccine-immunized individuals being used to treat
H5N1-infected patients (35, 39). Our group and others have
reported that H5 monoclonal antibodies show promising effi-
cacy for inhibition of rapidly disseminating H5N1 virus in
mouse models (7, 13, 26, 28). However, avian H5N1 viruses
continue to circulate in broad geographic regions and have
established regional genetic lineages with distinct antigenic
properties (6, 29). Therefore, it is necessary to identify MAbs
with broadly cross-protective and potent inhibitory properties
for therapeutic purposes.
Most of the neutralizing antibodies for influenza virus target
the globular head region of the HA molecule. Research
groups, including ours, have attempted to characterize MAbs
which bind to the conserved epitopes located on the HA1
subunit (7, 25, 31). Recently, several studies have reported on
MAbs which recognize a highly conserved helical region in the
membrane-proximal stem of HA1/HA2 and which demon-
strate heterosubtypic neutralizing abilities against H1, H2, H5,
H6, H8, and H9 subtype viruses (10, 30, 33). A universal
antibody for all subtypes of influenza A viruses could be an
ideal tool for the treatment of infections caused by antigeni-
cally diverse viruses. However, possession of broad cross-reac-
tivity must not compromise the binding affinity of the MAb for
HA molecules, as antibodies with potent inhibitory effects con-
stitute the most desirable therapeutic regime for the control of
acute infections, such as those caused by H5N1 virus.
Avian H5N1 virus has evolved rapidly in poultry in wide
geographic regions since 2003 (6, 29, 38). The clade 2 H5N1
viruses represent the major population; these have caused all
of the human infections in Indonesia (clade 2.1), Egypt (clade
2.2), and Vietnam and China (clade 2.3) since 2005. Most of
the previous studies were not able to verify the ability of anti-
bodies to neutralize all three of these antigenic groups of
H5N1 viruses and, in particular, the clade 2.3 H5N1 viruses,
which exhibit the most distinct antigenic properties (38). More
importantly, the efficacies in mouse models indicated in the
different studies could not be compared directly, due to the
different inoculation doses being used. While clinical trials of
treatments for H5N1 virus infection are difficult to conduct, as
H5N1 human cases are still rare and occur only sporadically, it
FIG. 6. Molecular modeling analysis of the mismatched residues of
the 37 hAb and H1202-34 humanized antibodies. CDR regions are
rendered in stick mode and blue. (a) The human residue Ile (green)
and murine residue Phe (orange) at position H:70 are shown super-
imposed. The distances between H70:F and the adjacent CDR resi-
dues are indicated by green lines labeled with the distance value. (b)
van der Waals interactions of L46:A (37 hAb) with the adjacent phenyl
on CDR residues. (c) van der Waals interactions of L46:L (H1202-34)
with the adjacent phenyl on CDR residues.
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FIG. 7. Efficacy of chimeric and humanized 13D4 MAb in protecting mice against lethal challenge with different H5N1 influenza virus strains.
Mice were challenged with lethal doses of A/VNM/1194/2004, A/IDN/5/2005, A/BH Goose/QH/15C/2005, or A/SZ/406H/2006 via the intranasal
route and treated intravenously with 20 mg per kg of body weight of 13D4 cAb or 37 hAb at 24 h after infection. Mice were monitored daily for
14 days for survival and body weight change. Control groups were injected with PBS at 24 h after infection. Log-rank tests calculated the P values
between the therapeutic group and control group to be 0.01 and the P values between the therapeutic groups to be 0.05.
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is important to evaluate the ability of various MAb clones to
protect mice from infection with antigenic variants of H5N1
virus and also their virus-neutralizing properties. The murine
13D4 MAb showed the broadest spectrum of reactivity against
41 H5N1 isolates belonging to 7 major genetic clades/subclades
(1, 2.1, 2.2, 2.3, 2.4, 8, and 9) and also efficiently protected mice
against lethal challenge with four H5N1 strains representing
the genetic variants which have caused human infections since
2003 (7). In addition to the strong neutralizing abilities and
broad cross-reactivity which 13D4 MAb possesses, it may be
further characterized by its binding to the conserved sites near
the receptor binding region of the HA1 molecule (7). Human-
ization of antibodies such as 13D4 provides a great opportunity
for the development of therapeutic antibodies for H5N1 virus
infection. This study showed that chimeric and humanized
13D4 antibodies in which variable domains from the murine
antibody were combined with human constant domains re-
tained the binding affinity and broad-spectrum reactivity of the
parental antibody.
The two main approaches applied in antibody humanization
involve rational and empirical methods (2). Rational methods
include CDR grafting, resurfacing, superhumanization, and
human string content optimization. Of these, CDR grafting,
which involves the transfer of CDRs of a murine antibody onto
a human framework sequence, is the most commonly used
method. Empirical methods rely on the generation of large
libraries of humanized variants, followed by selection of the
best clones using enrichment technologies. In the present
study, CDR grafting was combined with framework library
screening to humanize 13D4 H5 MAb. The human germ line
light- and heavy-chain sequences 1-39-01 and 1-69-04 were
selected as the framework for CDR grafting, as they showed
the highest degree of homology with the corresponding 13D4
MAb framework regions. This high-throughput screening tech-
nique makes the antibody humanization process simple and
highly efficient.
Although several humanized antibodies designed for treat-
ment of human infections have been reported in the literature
(7, 16, 30), none are yet available for clinical use. The process
of humanizing a broadly cross-reactive H5 monoclonal anti-
body and the molecular basis for the differences in the binding
affinity of the resulting humanized antibodies are described in
this report. The 13D4 chimeric and humanized antibodies
which have retained the broad reactivity and protective prop-
erties of the murine version may provide a model for develop-
ment of therapeutic antibodies for the treatment of human
H5N1 infections. In response to the rapid evolution of influ-
enza virus and the uncertainty as to which antigenically distinct
variants may emerge in the future, a combinatorial approach,
in which two groups of MAbs which target the HA1 and HA2
regions, respectively, are used, may provide an effective solu-
tion for the treatment of human infection with highly patho-
genic influenza A viruses.
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